Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
Nearby clinics
5th Avenue Suite
5th Avenue
Fifth Avenue
Lothrop Street
Fifth Avenue
Forbes Avenue
Fifth Avenue
The PROMOTE Research Project aims to understand individual variation and realize precision medicine No other chronic disease
5.
The goal of this long-term, prospective, observational research study is to understand what makes individuals with multiple sclerosis (MS) and related disorders differ from one another. Specifically, we aim to investigate the predictors of the individual differences in disease trajectory and treatment response using a wide range of biological, biometric, imaging, environmental, and clinical measur
![Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010–2019 - Neurology and Therapy](https://img4.findglocal.com/714/589/2831604307145894.jpg)
Our recent study examining the cost of treatments just got published.
https://link.springer.com/article/10.1007/s40120-022-00358-4
https://twitter.com/Neurology_Ther/status/1528768357826285569
Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010–2019 - Neurology and Therapy Introduction Comparisons of healthcare utilization and expenditure among multiple sclerosis (MS) disease-modifying therapies (DMTs) are limited. Methods In this retrospective cohort study using commercial insurance claims data of a US population (2010–2019), we compared healthcare utilization and ...
![Prospective Investigation of Multiple Sclerosis in the Three Rivers Region updated their address.](https://img4.findglocal.com/425/825/2627147384258255.jpg)
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region updated their address.
![Sustained Immunotherapy and Disability Accumulation in Secondary Progressive Multiple Sclerosis](https://img5.findglocal.com/947/732/2574956729477321.jpg)
In this observational cohort study of 1621 secondary progressive multiple sclerosis (SPMS) patients, researchers examined the association of relapse activity and immune disease-modifying treatments (DMT) with the rate of disability accumulation and wheelchair dependency. Higher relapse rate during the SPMS phase was associated with faster rate of disability accumulation. DMT for patients experiencing relapse during SPMS slowed the rate of disability accumulation and wheelchair dependency.
The concept of "active" SPMS is misleading, as it probably represents just the late stage of relapsing MS. Thus, it is not surprising that DMT for relapsing MS, including the late stage, reduces disability accumulation.
https://jamanetwork.com/journals/jamaneurology/article-abstract/2768700?casa_token=54Z-yegMo0oAAAAA:ULwJ8mv-OPABwSwXWiPk3XrK-KRg7lm_qfxai6RAIvHZgpObR5_706jw5N8u6M4QM0dmRl_yoBBe
Sustained Immunotherapy and Disability Accumulation in Secondary Progressive Multiple Sclerosis This cohort study uses data from the MSBase international registry to examine the association of demographic and clinical factors, including the presence of relapses and exposure to immunotherapy, with the rate of disability accumulation in patients with secondary progressive multiple sclerosis.
![WALK MS®](https://img3.findglocal.com/673/448/2569051736734487.jpg)
The National Multiple Sclerosis Society is dedicated to creating a world free of MS, but they can't do it without our help. It’s faster and easier than ever to support this cause. Your donation will drive groundbreaking research, provide life-changing services and guarantee a supportive community for those who need it most. Please visit Team: UPMC MS CHAMPIONS fundraising page to join our team or make a donation. By joining our team, you will be signing up for a great event and an important cause. Each mile we walk, each dollar we raise brings us that much closer to our goal – an end to MS.
Together, we will end MS. Simply click the link below to visit our page and make a donation.
https://secure.nationalmssociety.org/site/TR?fr_id=31744&pg=team&team_id=629269
WALK MS® Walk MS connects people living with MS and those who care about them.
![Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis](https://img5.findglocal.com/357/605/2567302703576057.jpg)
Sphingosine-1-phosphate receptor (S1P1R) is a promising target for immunomodulation in MS. The first S1P1R modulator, Fingolimod, received approval in 2010 for treatment of relapsing type of multiple sclerosis (MS). To address the side effect profile of fingolimod, there has been development of several selective S1P1R receptor modulators. Ponesimod is an oral selective S1P1R modulator that induces a rapid, dose-dependent, and reversible sequestration of lymphocytes in lymphoid organs. This phase 3 multicenter, double-blind randomized clinical trial compared ponesimod (20mg daily, n=567) to teriflunomide (14mg daily n=566), a pyrimidine synthesis inhibitor previously approved for relapsing MS. Randomization was stratified by use of MS disease modifying therapy in the 2 years prior (presence or absence) and baseline Expanded Disability Status Scale score (≤3.5 or >3.5). Ponesimod reduced the annualized relapse rate (30.5%), brain volume loss (0.34%), focal active inflammatory disease activity (56%) and fatigue (mean difference -3.57 on Fatigue Symptom and Impact Questionnaire–Relapsing Multiple Sclerosis), while the proportion of patients achieving the status of no evidence of disease activity was greater for ponesimod (25% v. 16%). There was no difference in time to confirmed disability accumulation. The side effect profile of ponesimod is similar to other S1P1-R modulators. While adverse events were similar between the two groups, treatment discontinuation was greater for ponesimod. The results from this study supports the efficacy superiority of ponesimod over teriflunomide in individuals with MS.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2777917?resultClick=24
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis This superiority study compares the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with relapsing multiple sclerosis.
Click here to claim your Sponsored Listing.
Videos (show all)
Category
Contact the practice
Telephone
Address
Pittsburgh, PA
15260
Opening Hours
8am - 5pm |
Pittsburgh
Do you have limited or no ability to use one or both hands due to a cervical spinal cord injury, or
4401 Penn Avenue
Pittsburgh, 15224
PIRC is an interdisciplinary research center operated by the Department of Pediatric Radiology at UP
Pittsburgh
Phone # - (412) - 440-8418 Email - [email protected] Twitter - @PittWELLStudy Instagram - @pittwell
3811 O'Hara Street
Pittsburgh, 15213
Center for Adolescent Reward, Rhythm, & Sleep (CARRS), University of Pittsburgh School of Medicine.
Pittsburgh, 15213
We are currently seeking depressed elderly adults with or without cognitive or memory problems to participate in our study. Participants will be compensated. Additional reimburseme...
200 Lothrop Street
Pittsburgh, 15213
The Alzheimer's Disease Research Center (ADRC) at the University of Pittsburgh is one of the nation's leading federally funded research centers specializing in the diagnosis of Alz...
Pittsburgh
Welcome! We are a research group located at the University of Pittsburgh in Pittsburgh, PA.
Pittsburgh
International leader in neurologic patient care, education, training and research of the brain, spine and nervous system.
Pittsburgh
Community-Based Research on Equity and Substance Use (CORES)
3601 Fifth Avenue, 5th Floor/Falk Medical Building
Pittsburgh, 15213
Pittsburgh dermatology office conducting research studies for various skin conditions.
100 N. Bellefield Avenue
Pittsburgh, 15213
We are a team of researchers at UPMC studying decision processes in depression, suicidal behavior, a
1400 Locust Street
Pittsburgh, 15219
A nationally recognized center of excellence that provides comprehensive services to individuals with spinal cord injury.